On December 30, 2021 Akari Therapeutics, Plc (Nasdaq: AKTX) ("Akari" or the "Company"), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, reported that it has entered into definitive agreements with institutional investors and accredited investors, led by existing investors of the Company, including Dr. Ray Prudo, the Company’s Chairman, to receive gross proceeds of approximately $6.0 million (Press release, Akari Therapeutics, DEC 30, 2021, View Source [SID1234598027]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In connection with the offering, the Company will issue approximately 4,310,839 registered American Depository Shares (ADSs) of Akari at a purchase price of $1.40 per ADS in a registered direct offering. Additionally, for each ADS purchased by investors, the investors will receive a registered warrant to purchase one-half ADS. The warrants will have an exercise price of $1.65 per ADS, will be exercisable upon their issuance and will expire five years from the issuance date. The closing of the offering is expected to take place on or about January 4, 2022, subject to the satisfaction of customary closing conditions.

Paulson Investment Company, LLC, is acting as the exclusive placement agent in connection with this offering.

The securities described above are being offered by Akari pursuant to an effective shelf registration statement on Form F-3 (File No. 333-251673) previously filed with the Securities and Exchange Commission (the "SEC") on December 23, 2020 and declared effective by the SEC on December 31, 2020. The offering of the securities will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

The Company will file a prospectus supplement and the accompanying base prospectus with the SEC relating to the securities being offered. When available, electronic copies of the prospectus supplement and the accompanying base prospectus may be obtained at the SEC’s website at View Source, or by contacting Donald A. Wojnowski Jr. of Paulson Investment Company, LLC, at (855) 653-3444 or at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein. There shall not be any offer, solicitation of an offer to buy, or sale of securities in any state or jurisdiction in which such an offering, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On December 30, 2021, Personalis, Inc., or the Company, reported that entered into an At-the-Market Sales Agreement, or the Sales Agreement, with BTIG, LLC, or BTIG, under which it may offer and sell its common stock having aggregate sales proceeds of up to $100.0 million from time to time through BTIG as its sales agent (Filing, 8-K, Personalis, DEC 30, 2021, View Source [SID1234597952]). Sales of the Company’s common stock through BTIG, if any, will be made by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, including without limitation sales made directly on the Nasdaq Global Market or any other existing trading market for its common stock. BTIG will use commercially reasonable efforts to sell the Company’s common stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay BTIG a commission of up to 3.0% of the gross sales proceeds of any common stock sold through BTIG under the Sales Agreement. The Company has also provided BTIG with customary indemnification rights.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company is not obligated to make any sales of common stock under the Sales Agreement. The offering of shares of the Company’s common stock pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all common stock subject to the Sales Agreement, or (ii) termination of the Sales Agreement in accordance with its terms.

The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which is filed herewith as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference. This Current Report on Form 8-K also incorporates by reference the Sales Agreement into the Registration Statement (as defined below).

The Company’s common stock is being offered and sold pursuant to the Company’s effective shelf registration statement on Form S-3 and an accompanying prospectus (Registration Statement No. 333-251824) declared effective by the U.S. Securities and Exchange Commission, or SEC, on January 8, 2021, or the Registration Statement, and a prospectus supplement dated December 30, 2021.

On December 30, 2021 Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, reported that it has signed an agreement with SequMed, a pioneer in single-cell omics technology innovation and applications in China (Press release, Mission Bio, DEC 30, 2021, View Source [SID1234597860]). The agreement will allow Mission Bio to expand its product and services offerings into China, a key region of growth for its geographical expansion strategy, enabling high quality single-cell sequence services using Mission Bio’s products to customers in mainland China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With this new and important collaboration, Mission Bio and SequMed will work jointly by integrating Mission Bio’s technology platform into SequMed’s clinical assay development and data analysis capabilities to co-develop novel single cell assays for early detection, medication guidance, and prognostic monitoring of cancers, as well as reproductive genetics applications. This partnership builds on Mission Bio’s commitment to providing high quality single-cell multi-omics with the Tapestri platform in China, where there is an increasing demand for single-cell innovation for clinical diagnosis.

"Tumor heterogeneity is always one of the biggest challenges for cancer therapy and the development of treatment resistance," said Yan Zhang, CEO of Mission Bio. "Our Tapestri single-cell sequencing solutions enable us to detect the co-occurring mutations within cancer cells, allowing us to understand the mechanisms of resistance at a granular level. We are excited to collaborate with SequMed. By integrating our single-cell technology with SequMed’s expertise in clinical assay development, we are committed to improving diagnosis, prognosis, and treatment of diseases in China."

Prof. Xinghua Victor Pan, Chairman of Technology Committee of SequMed, said, "We are dedicated to promoting the development and application of next-generation single-cell multi-omics technology in scientific and clinical research. We look forward to working with Mission Bio to develop novel single-cell assays for different diseases, from molecular mechanism elucidation to clinical medicine acceleration. With the synergies between the two collaborating parties, SequMed will enter into a new era, providing our customers in China with comprehensive solutions for personalized medicine."

On December 30, 2021 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, reported that it will present virtually at the 2022 Goldman Healthcare CEOs Unscripted Conference on Thursday, January 6, 2022, at 9:00 a.m. (EDT) (Press release, Thermo Fisher Scientific, DEC 30, 2021, View Source [SID1234597858]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com.

On December 30, 2021 Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, reported that Gritstone management will participate in the following upcoming investor conferences in January (Press release, Gritstone Oncology, DEC 30, 2021, View Source [SID1234597854]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference: JP Morgan 40th Annual Global Healthcare Conference
Presentation Date and Time: Thursday, January 13, 2022 at 8:15 a.m. ET
Presenter: Andrew Allen, M.D., Ph.D., co-founder, president, and chief executive officer

Conference: H.C. Wainwright BioConnect Conference 2022
Presentation Date and Time: Available beginning Monday, January 10, 2022 at 7:00 a.m. ET
Presenter: Andrew Allen, M.D., Ph.D., co-founder, president, and chief executive officer

Conference: B. Riley Securities’ 2022 Virtual Oncology Conference
Presentation Date and Time: Thursday, January 27, 2022 at 1:30 p.m. ET
Presenter: Andrew Allen, M.D., Ph.D., co-founder, president, and chief executive officer

Live webcasts of all presentations will be accessible via the Investors & Media section of the company’s website at View Source An archived replay will be accessible for 30 days following each event.